Anne Hall
Family · Westminster, CONPI 1194457937
Payments from drug & device makers
Across 137 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$635
- Pfizer$375
- AstraZeneca$219
- Novo Nordisk$166
- Novartis$118
- Amgen$110
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,816100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $635 |
| Pfizer | 19 | $375 |
| AstraZeneca(2 entities) | 11 | $219 |
| Novo Nordisk | 11 | $166 |
| Novartis | 5 | $118 |
| Amgen | 5 | $110 |
| Lilly USA, LLC | 6 | $106 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Boehringer Ingelheim | 3 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Merck | 4 | $68 |
| Sumitomo Pharma America, Inc. | 3 | $57 |
| Bayer | 3 | $55 |
| Harmony Biosciences LLC | 2 | $53 |
| Radius Health, Inc. | 2 | $53 |
| Johnson & Johnson | 2 | $53 |
| Sanofi-aventis U.S. LLC | 2 | $52 |
| Exact Sciences | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Nevro Corp. | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| GSK | 1 | $32 |
| Lundbeck LLC | 1 | $24 |
| Abbott | 1 | $24 |
| Phadia US Inc. | 1 | $24 |
| Edwards Lifesciences | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| Abiomed | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $13 |
How this compares
$2,816 in reported general payments places this provider in the 90th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 16 | $21,199 |
| MounjaroTirzepatide | 14 | $14,943 |
| FarxigaDapagliflozin Propanediol | 18 | $14,345 |
| EliquisApixaban | 16 | $12,616 |
| OzempicSemaglutide | 12 | $9,319 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,312 |
| Estradiol | 36 | $2,395 |
| SynthroidLevothyroxine Sodium | 21 | $1,273 |
| Gabapentin | 70 | $1,242 |
| Levothyroxine Sodium | 127 | $1,220 |
| Omeprazole | 60 | $1,137 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $1,050 |
| Losartan Potassium | 143 | $1,049 |
| Lisinopril | 157 | $1,031 |
| Atorvastatin Calcium | 131 | $837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $79 | $21,19916 claims |
| AstraZenecaFarxiga, Symbicort | $219 | $18,65831 claims |
| Lilly USA, LLCMounjaro | $106 | $14,94314 claims |
| PfizerEliquis | $375 | $12,61616 claims |
| Novo NordiskOzempic | $166 | $9,31912 claims |
| AbbVieSynthroid | $635 | $1,27321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,182 family providers in Colorado.
Other family in Westminster
- Laura GrahamLakewood$1.6M
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
- Teal MeffordThornton$63K
- Jacquita JordanColorado Springs$52K
- Stephanie HanenbergColorado Springs$40K
- Courtney WeirFort Collins$30K
- Katie NadingDenver$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.